The DBG has licensed an organ-on-chip technology to New Orleans biotech Obatala Sciences. Obatala will use the technology to build disease platforms for curing obesity, diabetes, and cancer. The collaboration has been covered by businesswire in Harvard Licenses Technology to Obatala Sciences to Advance Discovery in Obesity, Diabetes, and Cancer.